Biosimilar Insulin Industry Research Report 2023
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
Highlights
The global Biosimilar Insulin market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin.
The Biosimilar Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Biosimilar Insulin market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Biosimilar Insulin type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Biosimilar Insulin are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Biosimilar Insulin segment by Type
This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biosimilar Insulin market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biosimilar Insulin market.
Biosimilar Insulin segment by Distribution Channel
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biosimilar Insulin market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biosimilar Insulin industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilar Insulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilar Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Highlights
The global Biosimilar Insulin market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin.
The Biosimilar Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Biosimilar Insulin market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Eli Lilly
- Sanofi
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- Geropharm
- Biocon
- Wockhardt
Global markets are presented by Biosimilar Insulin type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Biosimilar Insulin are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Biosimilar Insulin segment by Type
- Biosimilar Insulin Glargine
- Biosimilar Insulin Lispro
- Other
This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biosimilar Insulin market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biosimilar Insulin market.
Biosimilar Insulin segment by Distribution Channel
- Hospital
- Retail Pharmacy
- Others
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biosimilar Insulin market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biosimilar Insulin industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilar Insulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilar Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Biosimilar Insulin Market Size (2018-2029) & (US$ Million)
2.2.2 Global Biosimilar Insulin Sales (2018-2029)
2.2.3 Global Biosimilar Insulin Market Average Price (2018-2029)
2.3 Biosimilar Insulin by Type
2.3.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
2.4 Biosimilar Insulin by Distribution Channel
2.4.1 Market Value Comparison by Distribution Channel (2018 VS 2022 VS 2029) & (US$ Million)
2.4.2 Hospital
2.4.3 Retail Pharmacy
2.4.4 Others
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Biosimilar Insulin Market Competitive Situation by Manufacturers (2018 Versus 2022)
3.2 Global Biosimilar Insulin Sales (K Unit) of Manufacturers (2018-2023)
3.3 Global Biosimilar Insulin Revenue of Manufacturers (2018-2023)
3.4 Global Biosimilar Insulin Average Price by Manufacturers (2018-2023)
3.5 Global Biosimilar Insulin Industry Ranking, 2021 VS 2022 VS 2023
3.6 Global Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Biosimilar Insulin, Product Type & Application
3.8 Global Manufacturers of Biosimilar Insulin, Date of Enter into This Industry
3.9 Global Biosimilar Insulin Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Eli Lilly
4.1.1 Eli Lilly Company Information
4.1.2 Eli Lilly Business Overview
4.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
4.1.5 Eli Lilly Recent Developments
4.2 Sanofi
4.2.1 Sanofi Company Information
4.2.2 Sanofi Business Overview
4.2.3 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.2.4 Sanofi Biosimilar Insulin Product Portfolio
4.2.5 Sanofi Recent Developments
4.3 Gan&Lee
4.3.1 Gan&Lee Company Information
4.3.2 Gan&Lee Business Overview
4.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
4.3.5 Gan&Lee Recent Developments
4.4 Tonghua Dongbao
4.4.1 Tonghua Dongbao Company Information
4.4.2 Tonghua Dongbao Business Overview
4.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
4.4.5 Tonghua Dongbao Recent Developments
4.5 United Laboratory
4.5.1 United Laboratory Company Information
4.5.2 United Laboratory Business Overview
4.5.3 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 United Laboratory Biosimilar Insulin Product Portfolio
6.5.5 United Laboratory Recent Developments
4.6 Geropharm
4.6.1 Geropharm Company Information
4.6.2 Geropharm Business Overview
4.6.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.6.4 Geropharm Biosimilar Insulin Product Portfolio
4.6.5 Geropharm Recent Developments
4.7 Biocon
4.7.1 Biocon Company Information
4.7.2 Biocon Business Overview
4.7.3 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.7.4 Biocon Biosimilar Insulin Product Portfolio
4.7.5 Biocon Recent Developments
6.8 Wockhardt
4.8.1 Wockhardt Company Information
4.8.2 Wockhardt Business Overview
4.8.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.8.4 Wockhardt Biosimilar Insulin Product Portfolio
4.8.5 Wockhardt Recent Developments
5 GLOBAL BIOSIMILAR INSULIN MARKET SCENARIO BY REGION
5.1 Global Biosimilar Insulin Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Biosimilar Insulin Sales by Region: 2018-2029
5.2.1 Global Biosimilar Insulin Sales by Region: 2018-2023
5.2.2 Global Biosimilar Insulin Sales by Region: 2024-2029
5.3 Global Biosimilar Insulin Revenue by Region: 2018-2029
5.3.1 Global Biosimilar Insulin Revenue by Region: 2018-2023
5.3.2 Global Biosimilar Insulin Revenue by Region: 2024-2029
5.4 North America Biosimilar Insulin Market Facts & Figures by Country
5.4.1 North America Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.4.2 North America Biosimilar Insulin Sales by Country (2018-2029)
5.4.3 North America Biosimilar Insulin Revenue by Country (2018-2029)
5.4.4 United States
5.4.5 Canada
5.5 Europe Biosimilar Insulin Market Facts & Figures by Country
5.5.1 Europe Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.5.2 Europe Biosimilar Insulin Sales by Country (2018-2029)
5.5.3 Europe Biosimilar Insulin Revenue by Country (2018-2029)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Biosimilar Insulin Market Facts & Figures by Country
5.6.1 Asia Pacific Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.6.2 Asia Pacific Biosimilar Insulin Sales by Country (2018-2029)
5.6.3 Asia Pacific Biosimilar Insulin Revenue by Country (2018-2029)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Biosimilar Insulin Market Facts & Figures by Country
5.7.1 Latin America Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.7.2 Latin America Biosimilar Insulin Sales by Country (2018-2029)
5.7.3 Latin America Biosimilar Insulin Revenue by Country (2018-2029)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country
5.8.1 Middle East and Africa Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.8.2 Middle East and Africa Biosimilar Insulin Sales by Country (2018-2029)
5.8.3 Middle East and Africa Biosimilar Insulin Revenue by Country (2018-2029)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Biosimilar Insulin Sales by Type (2018-2029)
6.1.1 Global Biosimilar Insulin Sales by Type (2018-2029) & (K Unit)
6.1.2 Global Biosimilar Insulin Sales Market Share by Type (2018-2029)
6.2 Global Biosimilar Insulin Revenue by Type (2018-2029)
6.2.1 Global Biosimilar Insulin Sales by Type (2018-2029) & (US$ Million)
6.2.2 Global Biosimilar Insulin Revenue Market Share by Type (2018-2029)
6.3 Global Biosimilar Insulin Price by Type (2018-2029)
7 SEGMENT BY DISTRIBUTION CHANNEL
7.1 Global Biosimilar Insulin Sales by Distribution Channel (2018-2029)
7.1.1 Global Biosimilar Insulin Sales by Distribution Channel (2018-2029) & (K Unit)
7.1.2 Global Biosimilar Insulin Sales Market Share by Distribution Channel (2018-2029)
7.2 Global Biosimilar Insulin Revenue by Distribution Channel (2018-2029)
6.2.1 Global Biosimilar Insulin Sales by Distribution Channel (2018-2029) & (US$ Million)
6.2.2 Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2018-2029)
7.3 Global Biosimilar Insulin Price by Distribution Channel (2018-2029)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Biosimilar Insulin Value Chain Analysis
8.1.1 Biosimilar Insulin Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Biosimilar Insulin Production Mode & Process
8.2 Biosimilar Insulin Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Biosimilar Insulin Distributors
8.2.3 Biosimilar Insulin Customers
9 GLOBAL BIOSIMILAR INSULIN ANALYZING MARKET DYNAMICS
9.1 Biosimilar Insulin Industry Trends
9.2 Biosimilar Insulin Industry Drivers
9.3 Biosimilar Insulin Industry Opportunities and Challenges
9.4 Biosimilar Insulin Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Biosimilar Insulin Market Size (2018-2029) & (US$ Million)
2.2.2 Global Biosimilar Insulin Sales (2018-2029)
2.2.3 Global Biosimilar Insulin Market Average Price (2018-2029)
2.3 Biosimilar Insulin by Type
2.3.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
2.4 Biosimilar Insulin by Distribution Channel
2.4.1 Market Value Comparison by Distribution Channel (2018 VS 2022 VS 2029) & (US$ Million)
2.4.2 Hospital
2.4.3 Retail Pharmacy
2.4.4 Others
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Biosimilar Insulin Market Competitive Situation by Manufacturers (2018 Versus 2022)
3.2 Global Biosimilar Insulin Sales (K Unit) of Manufacturers (2018-2023)
3.3 Global Biosimilar Insulin Revenue of Manufacturers (2018-2023)
3.4 Global Biosimilar Insulin Average Price by Manufacturers (2018-2023)
3.5 Global Biosimilar Insulin Industry Ranking, 2021 VS 2022 VS 2023
3.6 Global Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Biosimilar Insulin, Product Type & Application
3.8 Global Manufacturers of Biosimilar Insulin, Date of Enter into This Industry
3.9 Global Biosimilar Insulin Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Eli Lilly
4.1.1 Eli Lilly Company Information
4.1.2 Eli Lilly Business Overview
4.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
4.1.5 Eli Lilly Recent Developments
4.2 Sanofi
4.2.1 Sanofi Company Information
4.2.2 Sanofi Business Overview
4.2.3 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.2.4 Sanofi Biosimilar Insulin Product Portfolio
4.2.5 Sanofi Recent Developments
4.3 Gan&Lee
4.3.1 Gan&Lee Company Information
4.3.2 Gan&Lee Business Overview
4.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
4.3.5 Gan&Lee Recent Developments
4.4 Tonghua Dongbao
4.4.1 Tonghua Dongbao Company Information
4.4.2 Tonghua Dongbao Business Overview
4.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
4.4.5 Tonghua Dongbao Recent Developments
4.5 United Laboratory
4.5.1 United Laboratory Company Information
4.5.2 United Laboratory Business Overview
4.5.3 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 United Laboratory Biosimilar Insulin Product Portfolio
6.5.5 United Laboratory Recent Developments
4.6 Geropharm
4.6.1 Geropharm Company Information
4.6.2 Geropharm Business Overview
4.6.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.6.4 Geropharm Biosimilar Insulin Product Portfolio
4.6.5 Geropharm Recent Developments
4.7 Biocon
4.7.1 Biocon Company Information
4.7.2 Biocon Business Overview
4.7.3 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.7.4 Biocon Biosimilar Insulin Product Portfolio
4.7.5 Biocon Recent Developments
6.8 Wockhardt
4.8.1 Wockhardt Company Information
4.8.2 Wockhardt Business Overview
4.8.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2018-2023)
4.8.4 Wockhardt Biosimilar Insulin Product Portfolio
4.8.5 Wockhardt Recent Developments
5 GLOBAL BIOSIMILAR INSULIN MARKET SCENARIO BY REGION
5.1 Global Biosimilar Insulin Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Biosimilar Insulin Sales by Region: 2018-2029
5.2.1 Global Biosimilar Insulin Sales by Region: 2018-2023
5.2.2 Global Biosimilar Insulin Sales by Region: 2024-2029
5.3 Global Biosimilar Insulin Revenue by Region: 2018-2029
5.3.1 Global Biosimilar Insulin Revenue by Region: 2018-2023
5.3.2 Global Biosimilar Insulin Revenue by Region: 2024-2029
5.4 North America Biosimilar Insulin Market Facts & Figures by Country
5.4.1 North America Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.4.2 North America Biosimilar Insulin Sales by Country (2018-2029)
5.4.3 North America Biosimilar Insulin Revenue by Country (2018-2029)
5.4.4 United States
5.4.5 Canada
5.5 Europe Biosimilar Insulin Market Facts & Figures by Country
5.5.1 Europe Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.5.2 Europe Biosimilar Insulin Sales by Country (2018-2029)
5.5.3 Europe Biosimilar Insulin Revenue by Country (2018-2029)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Biosimilar Insulin Market Facts & Figures by Country
5.6.1 Asia Pacific Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.6.2 Asia Pacific Biosimilar Insulin Sales by Country (2018-2029)
5.6.3 Asia Pacific Biosimilar Insulin Revenue by Country (2018-2029)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Biosimilar Insulin Market Facts & Figures by Country
5.7.1 Latin America Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.7.2 Latin America Biosimilar Insulin Sales by Country (2018-2029)
5.7.3 Latin America Biosimilar Insulin Revenue by Country (2018-2029)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country
5.8.1 Middle East and Africa Biosimilar Insulin Market Size by Country: 2018 VS 2022 VS 2029
5.8.2 Middle East and Africa Biosimilar Insulin Sales by Country (2018-2029)
5.8.3 Middle East and Africa Biosimilar Insulin Revenue by Country (2018-2029)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Biosimilar Insulin Sales by Type (2018-2029)
6.1.1 Global Biosimilar Insulin Sales by Type (2018-2029) & (K Unit)
6.1.2 Global Biosimilar Insulin Sales Market Share by Type (2018-2029)
6.2 Global Biosimilar Insulin Revenue by Type (2018-2029)
6.2.1 Global Biosimilar Insulin Sales by Type (2018-2029) & (US$ Million)
6.2.2 Global Biosimilar Insulin Revenue Market Share by Type (2018-2029)
6.3 Global Biosimilar Insulin Price by Type (2018-2029)
7 SEGMENT BY DISTRIBUTION CHANNEL
7.1 Global Biosimilar Insulin Sales by Distribution Channel (2018-2029)
7.1.1 Global Biosimilar Insulin Sales by Distribution Channel (2018-2029) & (K Unit)
7.1.2 Global Biosimilar Insulin Sales Market Share by Distribution Channel (2018-2029)
7.2 Global Biosimilar Insulin Revenue by Distribution Channel (2018-2029)
6.2.1 Global Biosimilar Insulin Sales by Distribution Channel (2018-2029) & (US$ Million)
6.2.2 Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2018-2029)
7.3 Global Biosimilar Insulin Price by Distribution Channel (2018-2029)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Biosimilar Insulin Value Chain Analysis
8.1.1 Biosimilar Insulin Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Biosimilar Insulin Production Mode & Process
8.2 Biosimilar Insulin Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Biosimilar Insulin Distributors
8.2.3 Biosimilar Insulin Customers
9 GLOBAL BIOSIMILAR INSULIN ANALYZING MARKET DYNAMICS
9.1 Biosimilar Insulin Industry Trends
9.2 Biosimilar Insulin Industry Drivers
9.3 Biosimilar Insulin Industry Opportunities and Challenges
9.4 Biosimilar Insulin Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Distribution Channel (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Biosimilar Insulin Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)
Table 6. Global Biosimilar Insulin Sales (K Unit) of Manufacturers (2018-2023)
Table 7. Global Biosimilar Insulin Sales Market Share by Manufacturers (2018-2023)
Table 8. Global Biosimilar Insulin Revenue of Manufacturers (2018-2023)
Table 9. Global Biosimilar Insulin Revenue Share by Manufacturers (2018-2023)
Table 10. Global Market Biosimilar Insulin Average Price (US$/Unit) of Manufacturers (2018-2023)
Table 11. Global Biosimilar Insulin Industry Ranking, 2021 VS 2022 VS 2023
Table 12. Global Manufacturers of Biosimilar Insulin, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Eli Lilly Company Information
Table 17. Eli Lilly Business Overview
Table 18. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 19. Eli Lilly Biosimilar Insulin Product Portfolio
Table 20. Eli Lilly Recent Developments
Table 21. Sanofi Company Information
Table 22. Sanofi Business Overview
Table 23. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 24. Sanofi Biosimilar Insulin Product Portfolio
Table 25. Sanofi Recent Developments
Table 26. Gan&Lee Company Information
Table 27. Gan&Lee Business Overview
Table 28. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 29. Gan&Lee Biosimilar Insulin Product Portfolio
Table 30. Gan&Lee Recent Developments
Table 31. Tonghua Dongbao Company Information
Table 32. Tonghua Dongbao Business Overview
Table 33. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 34. Tonghua Dongbao Biosimilar Insulin Product Portfolio
Table 35. Tonghua Dongbao Recent Developments
Table 36. United Laboratory Company Information
Table 37. United Laboratory Business Overview
Table 38. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 39. United Laboratory Biosimilar Insulin Product Portfolio
Table 40. United Laboratory Recent Developments
Table 41. Geropharm Company Information
Table 42. Geropharm Business Overview
Table 43. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 44. Geropharm Biosimilar Insulin Product Portfolio
Table 45. Geropharm Recent Developments
Table 46. Biocon Company Information
Table 47. Biocon Business Overview
Table 48. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 49. Biocon Biosimilar Insulin Product Portfolio
Table 50. Biocon Recent Developments
Table 51. Wockhardt Company Information
Table 52. Wockhardt Business Overview
Table 53. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 54. Wockhardt Biosimilar Insulin Product Portfolio
Table 55. Wockhardt Recent Developments
Table 56. Global Biosimilar Insulin Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Global Biosimilar Insulin Sales by Region (2018-2023) & (K Unit)
Table 58. Global Biosimilar Insulin Sales Market Share by Region (2018-2023)
Table 59. Global Biosimilar Insulin Sales by Region (2024-2029) & (K Unit)
Table 60. Global Biosimilar Insulin Sales Market Share by Region (2024-2029)
Table 61. Global Biosimilar Insulin Revenue by Region (2018-2023) & (US$ Million)
Table 62. Global Biosimilar Insulin Revenue Market Share by Region (2018-2023)
Table 63. Global Biosimilar Insulin Revenue by Region (2024-2029) & (US$ Million)
Table 64. Global Biosimilar Insulin Revenue Market Share by Region (2024-2029)
Table 65. North America Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 66. North America Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 67. North America Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 68. North America Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 69. North America Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 70. Europe Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 72. Europe Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 73. Europe Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 75. Asia Pacific Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 76. Asia Pacific Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 77. Asia Pacific Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 78. Asia Pacific Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 79. Asia Pacific Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 80. Latin America Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 81. Latin America Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 82. Latin America Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 83. Latin America Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 84. Latin America Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 85. Middle East and Africa Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 86. Middle East and Africa Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 87. Middle East and Africa Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 88. Middle East and Africa Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 89. Middle East and Africa Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 90. Global Biosimilar Insulin Sales by Type (2018-2023) & (K Unit)
Table 91. Global Biosimilar Insulin Sales by Type (2024-2029) & (K Unit)
Table 92. Global Biosimilar Insulin Sales Market Share by Type (2018-2023)
Table 93. Global Biosimilar Insulin Sales Market Share by Type (2024-2029)
Table 94. Global Biosimilar Insulin Revenue by Type (2018-2023) & (US$ Million)
Table 95. Global Biosimilar Insulin Revenue by Type (2024-2029) & (US$ Million)
Table 96. Global Biosimilar Insulin Revenue Market Share by Type (2018-2023)
Table 97. Global Biosimilar Insulin Revenue Market Share by Type (2024-2029)
Table 98. Global Biosimilar Insulin Price by Type (2018-2023) & (US$/Unit)
Table 99. Global Biosimilar Insulin Price by Type (2024-2029) & (US$/Unit)
Table 100. Global Biosimilar Insulin Sales by Distribution Channel (2018-2023) & (K Unit)
Table 101. Global Biosimilar Insulin Sales by Distribution Channel (2024-2029) & (K Unit)
Table 102. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2018-2023)
Table 103. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2024-2029)
Table 104. Global Biosimilar Insulin Revenue by Distribution Channel (2018-2023) & (US$ Million)
Table 105. Global Biosimilar Insulin Revenue by Distribution Channel (2024-2029) & (US$ Million)
Table 106. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2018-2023)
Table 107. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2024-2029)
Table 108. Global Biosimilar Insulin Price by Distribution Channel (2018-2023) & (US$/Unit)
Table 109. Global Biosimilar Insulin Price by Distribution Channel (2024-2029) & (US$/Unit)
Table 110. Key Raw Materials
Table 111. Raw Materials Key Suppliers
Table 112. Biosimilar Insulin Distributors List
Table 113. Biosimilar Insulin Customers List
Table 114. Biosimilar Insulin Industry Trends
Table 115. Biosimilar Insulin Industry Drivers
Table 116. Biosimilar Insulin Industry Restraints
Table 117. Authors List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Distribution Channel (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Biosimilar Insulin Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)
Table 6. Global Biosimilar Insulin Sales (K Unit) of Manufacturers (2018-2023)
Table 7. Global Biosimilar Insulin Sales Market Share by Manufacturers (2018-2023)
Table 8. Global Biosimilar Insulin Revenue of Manufacturers (2018-2023)
Table 9. Global Biosimilar Insulin Revenue Share by Manufacturers (2018-2023)
Table 10. Global Market Biosimilar Insulin Average Price (US$/Unit) of Manufacturers (2018-2023)
Table 11. Global Biosimilar Insulin Industry Ranking, 2021 VS 2022 VS 2023
Table 12. Global Manufacturers of Biosimilar Insulin, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Eli Lilly Company Information
Table 17. Eli Lilly Business Overview
Table 18. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 19. Eli Lilly Biosimilar Insulin Product Portfolio
Table 20. Eli Lilly Recent Developments
Table 21. Sanofi Company Information
Table 22. Sanofi Business Overview
Table 23. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 24. Sanofi Biosimilar Insulin Product Portfolio
Table 25. Sanofi Recent Developments
Table 26. Gan&Lee Company Information
Table 27. Gan&Lee Business Overview
Table 28. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 29. Gan&Lee Biosimilar Insulin Product Portfolio
Table 30. Gan&Lee Recent Developments
Table 31. Tonghua Dongbao Company Information
Table 32. Tonghua Dongbao Business Overview
Table 33. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 34. Tonghua Dongbao Biosimilar Insulin Product Portfolio
Table 35. Tonghua Dongbao Recent Developments
Table 36. United Laboratory Company Information
Table 37. United Laboratory Business Overview
Table 38. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 39. United Laboratory Biosimilar Insulin Product Portfolio
Table 40. United Laboratory Recent Developments
Table 41. Geropharm Company Information
Table 42. Geropharm Business Overview
Table 43. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 44. Geropharm Biosimilar Insulin Product Portfolio
Table 45. Geropharm Recent Developments
Table 46. Biocon Company Information
Table 47. Biocon Business Overview
Table 48. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 49. Biocon Biosimilar Insulin Product Portfolio
Table 50. Biocon Recent Developments
Table 51. Wockhardt Company Information
Table 52. Wockhardt Business Overview
Table 53. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 54. Wockhardt Biosimilar Insulin Product Portfolio
Table 55. Wockhardt Recent Developments
Table 56. Global Biosimilar Insulin Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Global Biosimilar Insulin Sales by Region (2018-2023) & (K Unit)
Table 58. Global Biosimilar Insulin Sales Market Share by Region (2018-2023)
Table 59. Global Biosimilar Insulin Sales by Region (2024-2029) & (K Unit)
Table 60. Global Biosimilar Insulin Sales Market Share by Region (2024-2029)
Table 61. Global Biosimilar Insulin Revenue by Region (2018-2023) & (US$ Million)
Table 62. Global Biosimilar Insulin Revenue Market Share by Region (2018-2023)
Table 63. Global Biosimilar Insulin Revenue by Region (2024-2029) & (US$ Million)
Table 64. Global Biosimilar Insulin Revenue Market Share by Region (2024-2029)
Table 65. North America Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 66. North America Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 67. North America Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 68. North America Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 69. North America Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 70. Europe Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 72. Europe Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 73. Europe Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 75. Asia Pacific Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 76. Asia Pacific Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 77. Asia Pacific Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 78. Asia Pacific Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 79. Asia Pacific Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 80. Latin America Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 81. Latin America Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 82. Latin America Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 83. Latin America Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 84. Latin America Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 85. Middle East and Africa Biosimilar Insulin Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 86. Middle East and Africa Biosimilar Insulin Sales by Country (2018-2023) & (K Unit)
Table 87. Middle East and Africa Biosimilar Insulin Sales by Country (2024-2029) & (K Unit)
Table 88. Middle East and Africa Biosimilar Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 89. Middle East and Africa Biosimilar Insulin Revenue by Country (2024-2029) & (US$ Million)
Table 90. Global Biosimilar Insulin Sales by Type (2018-2023) & (K Unit)
Table 91. Global Biosimilar Insulin Sales by Type (2024-2029) & (K Unit)
Table 92. Global Biosimilar Insulin Sales Market Share by Type (2018-2023)
Table 93. Global Biosimilar Insulin Sales Market Share by Type (2024-2029)
Table 94. Global Biosimilar Insulin Revenue by Type (2018-2023) & (US$ Million)
Table 95. Global Biosimilar Insulin Revenue by Type (2024-2029) & (US$ Million)
Table 96. Global Biosimilar Insulin Revenue Market Share by Type (2018-2023)
Table 97. Global Biosimilar Insulin Revenue Market Share by Type (2024-2029)
Table 98. Global Biosimilar Insulin Price by Type (2018-2023) & (US$/Unit)
Table 99. Global Biosimilar Insulin Price by Type (2024-2029) & (US$/Unit)
Table 100. Global Biosimilar Insulin Sales by Distribution Channel (2018-2023) & (K Unit)
Table 101. Global Biosimilar Insulin Sales by Distribution Channel (2024-2029) & (K Unit)
Table 102. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2018-2023)
Table 103. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2024-2029)
Table 104. Global Biosimilar Insulin Revenue by Distribution Channel (2018-2023) & (US$ Million)
Table 105. Global Biosimilar Insulin Revenue by Distribution Channel (2024-2029) & (US$ Million)
Table 106. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2018-2023)
Table 107. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2024-2029)
Table 108. Global Biosimilar Insulin Price by Distribution Channel (2018-2023) & (US$/Unit)
Table 109. Global Biosimilar Insulin Price by Distribution Channel (2024-2029) & (US$/Unit)
Table 110. Key Raw Materials
Table 111. Raw Materials Key Suppliers
Table 112. Biosimilar Insulin Distributors List
Table 113. Biosimilar Insulin Customers List
Table 114. Biosimilar Insulin Industry Trends
Table 115. Biosimilar Insulin Industry Drivers
Table 116. Biosimilar Insulin Industry Restraints
Table 117. Authors List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Biosimilar InsulinProduct Picture
Figure 5. Global Biosimilar Insulin Revenue (US$ Million), 2018 VS 2022 VS 2029
Figure 6. Global Biosimilar Insulin Market Size (2018-2029) & (US$ Million)
Figure 7. Global Biosimilar Insulin Sales (2018-2029) & (K Unit)
Figure 8. Global Biosimilar Insulin Average Price (US$/Unit) & (2018-2029)
Figure 9. Biosimilar Insulin Glargine Product Picture
Figure 10. Biosimilar Insulin Lispro Product Picture
Figure 11. Other Product Picture
Figure 12. Hospital Product Picture
Figure 13. Retail Pharmacy Product Picture
Figure 14. Others Product Picture
Figure 15. Global Biosimilar Insulin Revenue Share by Manufacturers in 2022
Figure 16. Global Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
Figure 17. Global Manufacturers of Biosimilar Insulin, Date of Enter into This Industry
Figure 18. Global Top 5 and 10 Biosimilar Insulin Players Market Share by Revenue in 2022
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 20. Global Biosimilar Insulin Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. Global Biosimilar Insulin Sales by Region in 2022
Figure 22. Global Biosimilar Insulin Revenue by Region in 2022
Figure 23. North America Biosimilar Insulin Market Size by Country in 2022
Figure 24. North America Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 25. North America Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 26. United States Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe Biosimilar Insulin Market Size by Country in 2022
Figure 29. Europe Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 30. Europe Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 31. Germany Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Biosimilar Insulin Market Size by Country in 2022
Figure 37. Asia Pacific Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 38. Asia Pacific Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 39. China Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Japan Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. South Korea Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. India Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Australia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. China Taiwan Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Indonesia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Thailand Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Malaysia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Latin America Biosimilar Insulin Market Size by Country in 2022
Figure 49. Latin America Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 50. Latin America Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 51. Mexico Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East and Africa Biosimilar Insulin Market Size by Country in 2022
Figure 55. Middle East and Africa Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 56. Middle East and Africa Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 57. Turkey Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. Saudi Arabia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. UAE Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 60. Global Biosimilar Insulin Sales Market Share by Type (2018-2029)
Figure 61. Global Biosimilar Insulin Revenue Market Share by Type (2018-2029)
Figure 62. Global Biosimilar Insulin Price (US$/Unit) by Type (2018-2029)
Figure 63. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2018-2029)
Figure 64. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2018-2029)
Figure 65. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2018-2029)
Figure 66. Biosimilar Insulin Value Chain
Figure 67. Biosimilar Insulin Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. Biosimilar Insulin Industry Opportunities and Challenges
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Biosimilar InsulinProduct Picture
Figure 5. Global Biosimilar Insulin Revenue (US$ Million), 2018 VS 2022 VS 2029
Figure 6. Global Biosimilar Insulin Market Size (2018-2029) & (US$ Million)
Figure 7. Global Biosimilar Insulin Sales (2018-2029) & (K Unit)
Figure 8. Global Biosimilar Insulin Average Price (US$/Unit) & (2018-2029)
Figure 9. Biosimilar Insulin Glargine Product Picture
Figure 10. Biosimilar Insulin Lispro Product Picture
Figure 11. Other Product Picture
Figure 12. Hospital Product Picture
Figure 13. Retail Pharmacy Product Picture
Figure 14. Others Product Picture
Figure 15. Global Biosimilar Insulin Revenue Share by Manufacturers in 2022
Figure 16. Global Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
Figure 17. Global Manufacturers of Biosimilar Insulin, Date of Enter into This Industry
Figure 18. Global Top 5 and 10 Biosimilar Insulin Players Market Share by Revenue in 2022
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 20. Global Biosimilar Insulin Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. Global Biosimilar Insulin Sales by Region in 2022
Figure 22. Global Biosimilar Insulin Revenue by Region in 2022
Figure 23. North America Biosimilar Insulin Market Size by Country in 2022
Figure 24. North America Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 25. North America Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 26. United States Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe Biosimilar Insulin Market Size by Country in 2022
Figure 29. Europe Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 30. Europe Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 31. Germany Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Biosimilar Insulin Market Size by Country in 2022
Figure 37. Asia Pacific Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 38. Asia Pacific Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 39. China Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Japan Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. South Korea Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. India Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Australia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. China Taiwan Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Indonesia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Thailand Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Malaysia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Latin America Biosimilar Insulin Market Size by Country in 2022
Figure 49. Latin America Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 50. Latin America Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 51. Mexico Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East and Africa Biosimilar Insulin Market Size by Country in 2022
Figure 55. Middle East and Africa Biosimilar Insulin Sales Market Share by Country (2018-2029)
Figure 56. Middle East and Africa Biosimilar Insulin Revenue Market Share by Country (2018-2029)
Figure 57. Turkey Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. Saudi Arabia Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. UAE Biosimilar Insulin Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 60. Global Biosimilar Insulin Sales Market Share by Type (2018-2029)
Figure 61. Global Biosimilar Insulin Revenue Market Share by Type (2018-2029)
Figure 62. Global Biosimilar Insulin Price (US$/Unit) by Type (2018-2029)
Figure 63. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2018-2029)
Figure 64. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2018-2029)
Figure 65. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2018-2029)
Figure 66. Biosimilar Insulin Value Chain
Figure 67. Biosimilar Insulin Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. Biosimilar Insulin Industry Opportunities and Challenges
